# Linagliptin as Add on to Basal Insulin in the Elderly

> **NCT02240680** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 302 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** placebo
- **DRUG:** linagliptin

## Key facts

- **NCT ID:** NCT02240680
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-23
- **Primary completion:** 2017-04-18
- **Final completion:** 2017-04-25
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2018-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02240680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02240680, "Linagliptin as Add on to Basal Insulin in the Elderly". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02240680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*